Cancer
miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2.
Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, Koo KH, Park JW, Kim KS.
Mol Cells. 2009 Dec 31;28(6):521-7.
LIN28B confers radio-resistance through the posttranscriptional control of KRAS.
Jeong SH, Wu HG, Park WY.
Exp Mol Med. 2009 Dec 31;41(12):912-8.
MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines.
Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X.
Cancer Lett. 2009 Dec 28;286(2):217-22.
microRNA evaluation of unknown primary lesions in the head and neck.
Barker EV, Cervigne NK, Reis PP, Goswami RS, Xu W, Weinreb I, Irish JC, Kamel-Reid S.
Mol Cancer. 2009 Dec 23;8:127.
MicroRNA 29b functions in acute myeloid leukemia.
Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM.
Blood. 2009 Dec 17;114(26):5331-41.
Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma.
Cervigne NK, Reis PP, Machado J, Sadikovic B, Bradley G, Galloni NN, Pintilie M, Jurisica I, Perez-Ordonez B, Gilbert R, Gullane P, Irish
J, Kamel-Reid S.
Hum Mol Genet. 2009 Dec 15;18(24):4818-29.
Global changes in processing of mRNA 3' untranslated regions characterize clinically distinct cancer subtypes.
Singh P, Alley TL, Wright SM, Kamdar S, Schott W, Wilpan RY, Mills KD, Graber JH.
Cancer Res. 2009 Dec 15;69(24):9422-30.
Gene networks and microRNAs implicated in aggressive prostate cancer.
Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ, Thibodeau SN.
Cancer Res. 2009 Dec 15;69(24):9490-7.
Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma.
Scaruffi P, Stigliani S, Moretti S, Coco S, De Vecchi C, Valdora F, Garaventa A, Bonassi S, Tonini GP.
BMC Cancer. 2009 Dec 15;9:441.
Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas.
Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A.
Genes Dev. 2009 Dec 15;23(24):2806-11.
miR-19 is a key oncogenic component of mir-17-92.
Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L.
Genes Dev. 2009 Dec 15;23(24):2839-49.
Dissecting the dynamics of dysregulation of cellular processes in mouse mammary gland tumor.
Mentzen WI, Floris M, de la Fuente A.
BMC Genomics. 2009 Dec 13;10:601.
An integrated approach for experimental target identification of hypoxia-induced miR-210.
Fasanaro P, Greco S, Lorenzi M, Pescatori M, Brioschi M, Kulshreshtha R, Banfi C, Stubbs A, Calin GA, Ivan M, Capogrossi MC, Martelli
F.
J Biol Chem. 2009 Dec 11;284(50):35134-43.
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of
multiple myeloma.
Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S, Lombardi L, Bortoluzzi S, Neri A.
Blood. 2009 Dec 10;114(25):e20-6.
miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.
Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A,
Costinean S, Acunzo M, Condorelli G, Croce CM.
Cancer Cell. 2009 Dec 8;16(6):498-509.
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors.
Li M, Lee KF, Lu Y, Clarke I, Shih D, Eberhart C, Collins VP, Van Meter T, Picard D, Zhou L, Boutros PC, Modena P, Liang ML, Scherer
SW, Bouffet E, Rutka JT, Pomeroy SL, Lau CC, Taylor MD, Gajjar A, Dirks PB, Hawkins CE, Huang A.
Cancer Cell. 2009 Dec 8;16(6):533-46.
Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA
hypermethylation.
Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, Foley NH, Prenter S, Bray I, Watters KM, Higgins D, Stallings RL.
PLoS One. 2009 Dec 4;4(12):e8154.
Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration.
Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS.
Oncogene. 2009 Dec 3;28(48):4272-83.
The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors.
Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, Schmittgen T, Jiang J, diPierro CG, Li Y, Chiocca EA, Lee J, Fine H,
Abounader R, Lawler S, Purow B.
J Neurosci. 2009 Dec 2;29(48):15161-8.
MicroRNAs in cancer: small molecules with a huge impact.
Iorio MV, Croce CM.
J Clin Oncol. 2009 Dec 1;27(34):5848-56.
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer.
Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, Huang TH.
Cancer Res. 2009 Dec 1;69(23):9038-46.
Dicer1 functions as a haploinsufficient tumor suppressor.
Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, Kirsch DG, Golub TR, Jacks T.
Genes Dev. 2009 Dec 1;23(23):2700-4.
MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer.
Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, Calin GA, Mukherjee P.
Cancer Res. 2009 Dec 1;69(23):9090-5.
Epigenetic regulation of microRNA expression in colorectal cancer.
Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J.
Int J Cancer. 2009 Dec 1;125(11):2737-43.
[Up-regulation of p27(kip1) by miR-221/222 antisense oligonucleotides enhances the radiosensitivity of U251 glioblastoma]
Zhang C, Wang G, Kang C, Du Y, Pu P.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009 Dec;26(6):634-8.
Circulating miRNA and cancer diagnosis.
Tie Y, Liu B, Fu H, Zheng X.
Sci China C Life Sci. 2009 Dec;52(12):1117-22.
Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a
distinct subset of differentially expressed miRNAs.
Van Vlierberghe P, De Weer A, Mestdagh P, Feys T, De Preter K, De Paepe P, Lambein K, Vandesompele J, Van Roy N, Verhasselt B,
Poppe B, Speleman F.
Br J Haematol. 2009 Dec;147(5):686-90.
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.
McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C.
Cancer Metastasis Rev. 2009 Dec;28(3-4):335-44.
MicroRNA function in cancer: oncogene or a tumor suppressor?
Shenouda SK, Alahari SK.
Cancer Metastasis Rev. 2009 Dec;28(3-4):369-78.
Molecular diagnostics and predictors in thyroid cancer.
Nikiforova MN, Nikiforov YE.
Thyroid. 2009 Dec;19(12):1351-61.
Role of EBV in microRNA dysregulation in Burkitt lymphoma.
De Falco G, Antonicelli G, Onnis A, Lazzi S, Bellan C, Leoncini L.
Semin Cancer Biol. 2009 Dec;19(6):401-6.
MicroRNA regulation of cancer stem cells and therapeutic implications.
DeSano JT, Xu L.
AAPS J. 2009 Dec;11(4):682-92.
The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma.
Ohno M, Natsume A, Kondo Y, Iwamizu H, Motomura K, Toda H, Ito M, Kato T, Wakabayashi T.
Mol Cancer Res. 2009 Dec;7(12):2022-30.
MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma.
Kan T, Meltzer SJ.
Curr Opin Pharmacol. 2009 Dec;9(6):727-32.
Targeting miR-205 in breast cancer.
Wu H, Mo YY.
Expert Opin Ther Targets. 2009 Dec;13(12):1439-48.
The microRNA-17 approximately 92 cluster: still a miRacle?
Bonauer A, Dimmeler S.
Cell Cycle. 2009 Dec;8(23):3866-73.
MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness.
Evangelisti C, Florian MC, Massimi I, Dominici C, Giannini G, Galardi S, Buè MC, Massalini S, McDowell HP, Messi E, Gulino A, Farace
MG, Ciafrè SA.
FASEB J. 2009 Dec;23(12):4276-87.
n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon.
Davidson LA, Wang N, Shah MS, Lupton JR, Ivanov I, Chapkin RS.
Carcinogenesis. 2009 Dec;30(12):2077-84.
MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.
Shin S, Lee EM, Cha HJ, Bae S, Jung JH, Lee SM, Yoon Y, Lee H, Kim S, Kim H, Lee SJ, Park IC, Jin YW, An S.
Int J Oncol. 2009 Dec;35(6):1343-52.
MicroRNA expression in head and neck cancer associates with alcohol consumption and survival.
Avissar M, McClean MD, Kelsey KT, Marsit CJ.
Carcinogenesis. 2009 Dec;30(12):2059-63.
[Recent proceedings in epigenetics research of lung cancer]
Takai D.
Nippon Rinsho. 2009 Dec;67(12):2387-96.
MicroRNAs in normal and malignant myelopoiesis.
Pelosi E, Labbaye C, Testa U.
Leuk Res. 2009 Dec;33(12):1584-93.
Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer.
Weiss FU, Marques IJ, Woltering JM, Vlecken DH, Aghdassi A, Partecke LI, Heidecke CD, Lerch MM, Bagowski CP.
Gastroenterology. 2009 Dec;137(6):2136-45.e1-7.
Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles.
Fulci V, Colombo T, Chiaretti S, Messina M, Citarella F, Tavolaro S, Guarini A, Foà R, Macino G.
Genes Chromosomes Cancer. 2009 Dec;48(12):1069-82.
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.
Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton
J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T.
Nat Cell Biol. 2009 Dec;11(12):1487-95.
What is the relationship among microRNA-181, epithelial cell-adhesion molecule (EpCAM) and beta-catenin in hepatic cancer stem cells.
Li JP, Zheng JY, Du JJ, Zhang R, Yang AG.
Hepatology. 2009 Dec;50(6):2047-8
Genomic and proteomic biomarkers for cancer: a multitude of opportunities.
Tainsky MA.
Biochim Biophys Acta. 2009 Dec;1796(2):176-93.
ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.
Chen JQ, Russo J.
Biochim Biophys Acta. 2009 Dec;1796(2):162-75.
Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells.
Wang F, Fu XD, Zhou Y, Zhang Y.
BMB Rep. 2009 Nov 30;42(11):725-30.
MicroRNAs: novel regulators in the hallmarks of human cancer.
Ruan K, Fang X, Ouyang G.
Cancer Lett. 2009 Nov 28;285(2):116-26.
The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion.
Sossey-Alaoui K, Bialkowska K, Plow EF.
J Biol Chem. 2009 Nov 27;284(48):33019-29.
Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes.
Calin GA, Croce CM.
Blood. 2009 Nov 26;114(23):4761-70.
Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types.
Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, Yakhini Z.
PLoS One. 2009 Nov 25;4(11):e8003.
AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations.
Robbiani DF, Bunting S, Feldhahn N, Bothmer A, Camps J, Deroubaix S, McBride KM, Klein IA, Stone G, Eisenreich TR, Ried T,
Nussenzweig A, Nussenzweig MC.
Mol Cell. 2009 Nov 25;36(4):631-41.
MicroRNA 125a and its regulation of the p53 tumor suppressor gene.
Zhang Y, Gao JS, Tang X, Tucker LD, Quesenberry P, Rigoutsos I, Ramratnam B.
FEBS Lett. 2009 Nov 19;583(22):3725-30.
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells.
Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J.
Oncogene. 2009 Nov 19;28(46):4065-74.
[Molecular diagnosis of malignant lymphomas]
Holte H, Kvaløy S, Delabie J, Trøen G, Smeland EB.
Tidsskr Nor Laegeforen. 2009 Nov 19;129(22):2352-6.
A cell motility screen reveals role for MARCKS-related protein in adherens junction formation and tumorigenesis.
Finlayson AE, Freeman KW.
PLoS One. 2009 Nov 18;4(11):e7833.
Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of
undifferentiated proliferative states.
Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM, Boardman LA, Cunningham JM,
Subramanian S, Wang L, Smyrk TC, Rodrigues CM, Thibodeau SN, Steer CJ.
BMC Cancer. 2009 Nov 18;9:401.
Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA
expression with survival.
Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, Alcock L, Mestdagh P, Vandesompele J, Speleman F, London WB,
McGrady PW, Higgins DG, O'Meara A, O'Sullivan M, Stallings RL.
PLoS One. 2009 Nov 16;4(11):e7850.
Yin and yang: cancer-implicated miRNAs that have it both ways.
Huse JT, Holland EC.
Cell Cycle. 2009 Nov 15;8(22):3611-2.
Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis.
Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA.
Genes Dev. 2009 Nov 15;23(22):2592-7.
Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone.
Liu S, Goldstein RH, Scepansky EM, Rosenblatt M.
Cancer Res. 2009 Nov 15;69(22):8742-51.
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application.
Slaby O, Svoboda M, Michalek J, Vyzula R.
Mol Cancer. 2009 Nov 14;8:102.
MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia.
Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ.
PLoS One. 2009 Nov 13;4(11):e7826.
MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation.
Song G, Zhang Y, Wang L.
J Biol Chem. 2009 Nov 13;284(46):31921-7.
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.
Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K.
J Biol Chem. 2009 Nov 13;284(46):32015-27.
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation.
Iliopoulos D, Hirsch HA, Struhl K.
Cell. 2009 Nov 13;139(4):693-706.
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes.
Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, Testa U, Pelosi E, Piaggio G, Sacchi A, Lavorgna S, Lo-Coco F,
Blandino G, Levrero M, Rizzo MG.
Oncogene. 2009 Nov 12;28(45):4034-40.
Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines.
Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellström K, Sahlberg N, Kristensen VN,
Børresen-Dale AL, Saviranta P, Perälä M, Kallioniemi O.
Oncogene. 2009 Nov 5;28(44):3926-36.
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and
invasion in human breast cancer.
Li XF, Yan PJ, Shao ZM.
Oncogene. 2009 Nov 5;28(44):3937-48.
miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221.
Kotani A, Ha D, Hsieh J, Rao PK, Schotte D, den Boer ML, Armstrong SA, Lodish HF.
Blood. 2009 Nov 5;114(19):4169-78.
Let-7a elevates p21(WAF1) levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells.
He X, Duan C, Chen J, Ou-Yang X, Zhang Z, Li C, Peng H.
FEBS Lett. 2009 Nov 3;583(21):3501-7.
Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.
Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G.
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18740-4.
3'UTR mediated regulation of the cyclin D1 proto-oncogene.
Deshpande A, Pastore A, Deshpande AJ, Zimmermann Y, Hutter G, Weinkauf M, Buske C, Hiddemann W, Dreyling M.
Cell Cycle. 2009 Nov 1;8(21):3584-92.
MicroRNA responses and stress granule formation modulate the DNA damage response.
Pothof J, Verkaik NS, Hoeijmakers JH, van Gent DC.
Cell Cycle. 2009 Nov 1;8(21):3462-8.
MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis.
Valastyan S, Weinberg RA.
Cell Cycle. 2009 Nov 1;8(21):3506-12.
Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.
Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Bénès V, Roché H, Dalenc F, Auboeuf D, Millevoi S, Vagner S.
Cancer Res. 2009 Nov 1;69(21):8332-40.
Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK
network.
Zaidi SK, Dowdy CR, van Wijnen AJ, Lian JB, Raza A, Stein JL, Croce CM, Stein GS.
Cancer Res. 2009 Nov 1;69(21):8249-55.
Distinct microRNA alterations characterize high- and low-grade bladder cancer.
Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larré S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M,
Harris AL, Hamdy FC.
Cancer Res. 2009 Nov 1;69(21):8472-81.
Epstein-Barr virus infection leads to partial phenotypic reversion of terminally differentiated malignant B cells.
Anastasiadou E, Vaeth S, Cuomo L, Boccellato F, Vincenti S, Cirone M, Presutti C, Junker S, Winberg G, Frati L, Wade PA, Faggioni A,
Trivedi P.
Cancer Lett. 2009 Nov 1;284(2):165-74.
MicroRNA-125a represses cell growth by targeting HuR in breast cancer.
Guo X, Wu Y, Hartley RS.
RNA Biol. 2009 Nov-Dec;6(5):575-83.
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.
Kent OA, Mullendore M, Wentzel EA, López-Romero P, Tan AC, Alvarez H, West K, Ochs MF, Hidalgo M, Arking DE, Maitra A, Mendell JT.
Cancer Biol Ther. 2009 Nov;8(21):2013-24.
[Epigenetic changes and cancer]
Hamelin R.
Ann Pathol. 2009 Nov;29 Spec No 1:S17-8.
[Clinicopathological significance of microRNA-21 and miR-125 expression in colorectal cancer]
Zhang Y, Zhou ZG, Wang L, Zhang P, Wang MJ, Cui CF, Guan JT, Chen KL, Zhan L.
Zhonghua Wei Chang Wai Ke Za Zhi. 2009 Nov;12(6):623-6.
Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells.
Tsai KW, Kao HW, Chen HC, Chen SJ, Lin WC.
Epigenetics. 2009 Nov;4(8):587-92.
Micro management: understanding how diesel exhaust particles alter cellular processes.
Washam C.
Environ Health Perspect. 2009 Nov;117(11):A504.
Disruption of microRNA expression in human airway cells by diesel exhaust particles is linked to tumorigenesis-associated pathways.
Jardim MJ, Fry RC, Jaspers I, Dailey L, Diaz-Sanchez D.
Environ Health Perspect. 2009 Nov;117(11):1745-51.
MicroRNA expression in chronic lymphocytic leukaemia.
Lawrie CH, Ballabio E, Dyar OJ, Jones M, Ventura R, Chi J, Tramonti D, Gooding S, Boultwood J, Wainscoat JS, Hatton CS, Schuh A.
Br J Haematol. 2009 Nov;147(3):398-402.
MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells.
Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM.
FEBS J. 2009 Nov;276(22):6689-700.
MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells.
Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, Liu T, Tang H.
IUBMB Life. 2009 Nov;61(11):1075-82.
MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma.
Yamamoto Y, Kosaka N, Tanaka M, Koizumi F, Kanai Y, Mizutani T, Murakami Y, Kuroda M, Miyajima A, Kato T, Ochiya T.
Biomarkers. 2009 Nov;14(7):529-38.
Expression profile of microRNAs in c-Myc induced mouse mammary tumors.
Sun Y, Wu J, Wu SH, Thakur A, Bollig A, Huang Y, Liao DJ.
Breast Cancer Res Treat. 2009 Nov;118(1):185-96.
MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines.
Muniyappa MK, Dowling P, Henry M, Meleady P, Doolan P, Gammell P, Clynes M, Barron N.
Eur J Cancer. 2009 Nov;45(17):3104-18.
Screening for microRNAs in myelodysplastic syndromes.
Eklund EA, Platanias LC.
Leuk Lymphoma. 2009 Nov;50(11):1735-6.
Hematopoiesis-related microRNA expression in myelodysplastic syndromes.
Pons A, Nomdedeu B, Navarro A, Gaya A, Gel B, Diaz T, Valera S, Rozman M, Belkaid M, Montserrat E, Monzo M.
Leuk Lymphoma. 2009 Nov;50(11):1854-9.
Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma.
Unno K, Zhou Y, Zimmerman T, Platanias LC, Wickrema A.
Leuk Lymphoma. 2009 Nov;50(11):1865-71.
[The roles of miR-17-92 cluster in mammal development and tumorigenesis]
ZHANG ZW, AN Y, TENG CB.
Yi Chuan. 2009 Nov;31(11):1094-100.
MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo.
Liu B, Peng XC, Zheng XL, Wang J, Qin YW.
Lung Cancer. 2009 Nov;66(2):169-75.
Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications.
Menon MP, Khan A.
J Clin Pathol. 2009 Nov;62(11):978-85.
MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?
Mardin WA, Mees ST.
Ann Surg Oncol. 2009 Nov;16(11):3183-9.
Genetic lesions in chronic lymphocytic leukemia: clinical implications.
Montserrat E, Moreno C.
Curr Opin Oncol. 2009 Nov;21(6):609-14.
The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells.
Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG.
Neoplasia. 2009 Nov;11(11):1208-15.
Role of miRNAs in lung cancer.
Cho WC.
Expert Rev Mol Diagn. 2009 Nov;9(8):773-6.
miR-34b/miR-34c: a regulator of TCL1 expression in 11q- chronic lymphocytic leukaemia?
Cardinaud B, Moreilhon C, Marcet B, Robbe-Sermesant K, LeBrigand K, Mari B, Eclache V, Cymbalista F, Raynaud S, Barbry P.
Leukemia. 2009 Nov;23(11):2174-7.
The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms.
Manni I, Artuso S, Careccia S, Rizzo MG, Baserga R, Piaggio G, Sacchi A.
FASEB J. 2009 Nov;23(11):3957-66.
miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J, Monzo M.
Carcinogenesis. 2009 Nov;30(11):1903-9.
Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer.
Long XB, Sun GB, Hu S, Liang GT, Wang N, Zhang XH, Cao PP, Zhen HT, Cui YH, Liu Z.
Oncol Rep. 2009 Nov;22(5):1189-95.
MicroRNAs: tools for cancer diagnostics.
Paranjape T, Slack FJ, Weidhaas JB.
Gut. 2009 Nov;58(11):1546-54.
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin
signaling pathway.
Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C,
Gusella JF, Krichevsky AM, Breakefield XO.
Mol Cell Biol. 2009 Nov;29(21):5923-40.
Opposite expression pattern of Src kinase Lyn in acute and chronic haematological malignancies.
Hussein K, von Neuhoff N, Büsche G, Buhr T, Kreipe H, Bock O.
Ann Hematol. 2009 Nov;88(11):1059-67.
Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells.
Akao Y, Nakagawa Y, Iio A, Naoe T.
Leuk Res. 2009 Nov;33(11):1530-8.
Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration.
Lei Z, Li B, Yang Z, Fang H, Zhang GM, Feng ZH, Huang B.
PLoS One. 2009 Oct 29;4(10):e7629.
Karyotype-specific microRNA signature in chronic lymphocytic leukemia.
Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, Volinia S, Ferracin M, Palatini J, Balatti V, Alder H, Negrini M,
Kipps TJ, Croce CM.
Blood. 2009 Oct 29;114(18):3872-9.
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.
Clapé C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, Iborra F, Avancès C, Villalba M, Culine S, Fajas L.
PLoS One. 2009 Oct 26;4(10):e7542.
MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development.
Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, Qu J, Tu L.
J Biol Chem. 2009 Oct 23;284(43):29596-604.
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.
Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, Otterson GA, Nana-Sinkam SP.
Biochem Biophys Res Commun. 2009 Oct 23;388(3):483-9.
MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical
carcinoma cells.
Yao Q, Xu H, Zhang QQ, Zhou H, Qu LH.
Biochem Biophys Res Commun. 2009 Oct 23;388(3):539-42.
Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma.
Radhakrishnan A, Badhrinarayanan N, Biswas J, Krishnakumar S.
Mol Vis. 2009 Oct 22;15:2146-54.
Identification of differentially expressed microRNAs by microarray: a possible role for microRNAs gene in medulloblastomas.
Liu W, Gong YH, Chao TF, Peng XZ, Yuan JG, Ma ZY, Jia G, Zhao JZ.
Chin Med J (Engl). 2009 Oct 20;122(20):2405-11.
Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer.
Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A, Raponi M.
BMC Cancer. 2009 Oct 20;9:374.
MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1.
Song H, Bu G.
Biochem Biophys Res Commun. 2009 Oct 16;388(2):400-5.
MYC, microRNAs and glutamine addiction in cancers.
Dang CV.
Cell Cycle. 2009 Oct 15;8(20):3243-5.
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells.
Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ Jr, Lazo JS, Wang Z, Zhang L, Yu J.
Cancer Res. 2009 Oct 15;69(20):8157-65.
miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by
targeting CDK6 and CDC25A.
Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, Yu Q.
Genes Dev. 2009 Oct 15;23(20):2388-93.
DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1.
Lerner M, Harada M, Lovén J, Castro J, Davis Z, Oscier D, Henriksson M, Sangfelt O, Grandér D, Corcoran MM.
Exp Cell Res. 2009 Oct 15;315(17):2941-52.
Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer
cells.
Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Jutooru I, Chadalapaka G, Wu F, Mertens-Talcott S, Vanderlaag K, Cho SD,
Smith R 3rd, Safe S.
Int J Cancer. 2009 Oct 15;125(8):1965-74.
Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression.
Edmonds MD, Hurst DR, Vaidya KS, Stafford LJ, Chen D, Welch DR.
Int J Cancer. 2009 Oct 15;125(8):1778-85.
MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells.
Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K, Tsichlis PN.
Sci Signal. 2009 Oct 13;2(92):ra62.
Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples.
He C, Xiong J, Xu X, Lu W, Liu L, Xiao D, Wang D.
Biochem Biophys Res Commun. 2009 Oct 9;388(1):35-40.
Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell
lymphoma/leukemia.
Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo YM, Iwamoto K, Yamashita J, Saitoh H, Kameoka Y, Shimizu N, Ichinohasama R,
Sawada K.
Blood. 2009 Oct 8;114(15):3265-75.
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.
Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J, Kutsch N, Krause G, Mayr
C, Rosenwald A, Plass C, Schultze JL, Hallek M, Wendtner CM.
Blood. 2009 Oct 8;114(15):3255-64.
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties.
Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS.
Oncogene. 2009 Oct 8;28(40):3526-36.
MicroRNA expression, survival, and response to interferon in liver cancer.
Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J,
Tang ZY, Sun HC, Wang XW.
N Engl J Med. 2009 Oct 8;361(15):1437-47.
Micromanaging cancer.
Lieberman J.
N Engl J Med. 2009 Oct 8;361(15):1500-1.
miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments.
Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP, Meese E.
BMC Cancer. 2009 Oct 6;9:353.
MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB.
PLoS One. 2009 Oct 2;4(10):e7314.
Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21.
de Oliveira PE, Zhang L, Wang Z, Lazo JS.
Cell Cycle. 2009 Oct 1;8(19):3157-64.
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma.
Navarro A, Diaz T, Martinez A, Gaya A, Pons A, Gel B, Codony C, Ferrer G, Martinez C, Montserrat E, Monzo M.
Blood. 2009 Oct 1;114(14):2945-51.
Metastamir: the field of metastasis-regulatory microRNA is spreading.
Hurst DR, Edmonds MD, Welch DR.
Cancer Res. 2009 Oct 1;69(19):7495-8.
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.
Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, Lopes B, Schiff D, Purow
B, Abounader R.
Cancer Res. 2009 Oct 1;69(19):7569-76.
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival.
Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson
AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC.
Clin Cancer Res. 2009 Oct 1;15(19):6192-200.
Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.
Drake KM, Ruteshouser EC, Natrajan R, Harbor P, Wegert J, Gessler M, Pritchard-Jones K, Grundy P, Dome J, Huff V, Jones C, Aldred
MA.
Clin Cancer Res. 2009 Oct 1;15(19):5985-92.
Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer.
Rossi G, Papotti M, Barbareschi M, Graziano P, Pelosi G.
J Clin Oncol. 2009 Oct 1;27(28):e141-2
HOX D13 expression across 79 tumor tissue types.
Cantile M, Franco R, Tschan A, Baumhoer D, Zlobec I, Schiavo G, Forte I, Bihl M, Liguori G, Botti G, Tornillo L, Karamitopoulou-Diamantis
E, Terracciano L, Cillo C.
Int J Cancer. 2009 Oct 1;125(7):1532-41.
[Clinical and cytogenetic factors of prognosis in glial tumors of the brain]
Dreval' ON, Belokhvostov AS, Feniksov VM.
Zh Vopr Neirokhir Im N N Burdenko. 2009 Oct-Dec;(4):7-12
Cholesteatoma growth and proliferation: posttranscriptional regulation by microRNA-21.
Friedland DR, Eernisse R, Erbe C, Gupta N, Cioffi JA.
Otol Neurotol. 2009 Oct;30(7):998-1005.
Microarray profile of micro-ribonucleic acid in tumor tissue from cervical squamous cell carcinoma without human papillomavirus.
Zhang Y, Dai Y, Huang Y, Ma L, Yin Y, Tang M, Hu C.
J Obstet Gynaecol Res. 2009 Oct;35(5):842-9.
Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic
adenocarcinoma.
Park JK, Lee EJ, Esau C, Schmittgen TD.
Pancreas. 2009 Oct;38(7):e190-9.
A short hairpin DNA analogous to miR-125b inhibits C-Raf expression, proliferation, and survival of breast cancer cells.
Hofmann MH, Heinrich J, Radziwil G, Moelling K.
Mol Cancer Res. 2009 Oct;7(10):1635-44.
[Progress in the molecular analysis of infant leukemias]
Ishii E.
Rinsho Ketsueki. 2009 Oct;50(10):1500-5.
Differentially expressed microRNAs in small cell lung cancer.
Miko E, Czimmerer Z, Csánky E, Boros G, Buslig J, Dezso B, Scholtz B.
Exp Lung Res. 2009 Oct;35(8):646-64.
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.
To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE.
Mol Cancer Ther. 2009 Oct;8(10):2959-68.
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets.
Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A.
J Pathol. 2009 Oct;219(2):214-21.
Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening.
Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ.
Gut. 2009 Oct;58(10):1375-81.
Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b.
Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T.
Mol Pharmacol. 2009 Oct;76(4):702-9.
miR(acle)s - new players in the regulation of known suspects.
Müller DW, Bosserhoff AK.
Pigment Cell Melanoma Res. 2009 Oct;22(5):525-6.
Identification of specific microRNAs responding to low and high dose gamma-irradiation in the human lymphoblast line IM9.
Cha HJ, Seong KM, Bae S, Jung JH, Kim CS, Yang KH, Jin YW, An S.
Oncol Rep. 2009 Oct;22(4):863-8.
Plasma microRNAs: a potential biomarker for colorectal cancer?
Schetter AJ, Harris CC.
Gut. 2009 Oct;58(10):1318-9.
The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs.
Persson H, Kvist A, Vallon-Christersson J, Medstrand P, Borg A, Rovira C.
Nat Cell Biol. 2009 Oct;11(10):1268-71.
MicroRNA-122 might be a double-edged sword in hepatocellular carcinoma.
Zhang R, Wang L, Yu GR, Zhang X, Yao LB, Yang AG.
Hepatology. 2009 Oct;50(4):1322-3.
Epidermal growth factor receptor-regulated miR-125a-5p--a metastatic inhibitor of lung cancer.
Wang G, Mao W, Zheng S, Ye J.
FEBS J. 2009 Oct;276(19):5571-8.
MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1.
Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, Li X, Tang H.
FEBS J. 2009 Oct;276(19):5537-46.
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice.
Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, Schmittgen TD, Croce C, Ghoshal K, Jacob ST.
Hepatology. 2009 Oct;50(4):1152-61.
Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells.
Dalgard CL, Gonzalez M, deNiro JE, O'Brien JM.
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4542-51.
Causes and consequences of microRNA dysregulation in cancer.
Croce CM.
Nat Rev Genet. 2009 Oct;10(10):704-14.
Microarray analysis of microRNA expression in renal clear cell carcinoma.
Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, Hu C, Zhang L.
Eur J Surg Oncol. 2009 Oct;35(10):1119-23.
Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH).
Munker R, Nordberg ML, Veillon D, Williams BJ, Roggero A, Kern W, Dicker F, Haferlach T.
Leuk Res. 2009 Oct;33(10):1405-8.
Analysis of microRNA expression profiles during the cell cycle in synchronized HeLa cells.
Zhou JY, Ma WL, Liang S, Zeng Y, Shi R, Yu HL, Xiao WW, Zheng WL.
BMB Rep. 2009 Sep 30;42(9):593-8.
miR-200 enhances mouse breast cancer cell colonization to form distant metastases.
Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J.
PLoS One. 2009 Sep 29;4(9):e7181.
Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3.
Huang B, Vassilev LT.
Aging (Albany NY). 2009 Sep 25;1(10):845-54.
Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL).
Hanlon K, Rudin CE, Harries LW.
PLoS One. 2009 Sep 25;4(9):e7169.
Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the
Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy
resistance in breast tumor cells.
Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E.
J Biol Chem. 2009 Sep 25;284(39):26533-46.
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p
deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S.
Blood. 2009 Sep 24;114(13):2589-97.
MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt
phosphorylation.
Lee KH, Chen YL, Yeh SD, Hsiao M, Lin JT, Goan YG, Lu PJ.
Oncogene. 2009 Sep 24;28(38):3360-70.
Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung
cancers.
Ebi H, Sato T, Sugito N, Hosono Y, Yatabe Y, Matsuyama Y, Yamaguchi T, Osada H, Suzuki M, Takahashi T.
Oncogene. 2009 Sep 24;28(38):3371-9.
mir-210: a sensor for hypoxic stress during tumorigenesis.
Mathew LK, Simon MC.
Mol Cell. 2009 Sep 24;35(6):737-8.
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation.
Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ.
Mol Cell. 2009 Sep 24;35(6):856-67.
MicroRNA-122a functions as a novel tumor suppressor downstream of adenomatous polyposis coli in gastrointestinal cancers.
Wang X, Lam EK, Zhang J, Jin H, Sung JJ.
Biochem Biophys Res Commun. 2009 Sep 18;387(2):376-80.
Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis.
Yan HL, Xue G, Mei Q, Wang YZ, Ding FX, Liu MF, Lu MH, Tang Y, Yu HY, Sun SH.
EMBO J. 2009 Sep 16;28(18):2719-32.
Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma.
Schetter AJ, Nguyen GH, Bowman ED, Mathé EA, Yuen ST, Hawkes JE, Croce CM, Leung SY, Harris CC.
Clin Cancer Res. 2009 Sep 15;15(18):5878-87.
MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X.
Clin Cancer Res. 2009 Sep 15;15(18):5744-52.
micRo-manageMeNT of MYC during hypoxia.
Morrish F.
Cell Cycle. 2009 Sep 15;8(18):2865.
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth.
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT,
Lupold SE.
Cancer Res. 2009 Sep 15;69(18):7165-9.
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression.
Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM.
Genes Dev. 2009 Sep 15;23(18):2140-51.
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D.
Genes Dev. 2009 Sep 15;23(18):2152-65.
miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer.
Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ.
J Biol Chem. 2009 Sep 11;284(37):24696-704.
MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in
human esophageal cancer.
Lee KH, Goan YG, Hsiao M, Lee CH, Jian SH, Lin JT, Chen YL, Lu PJ.
Exp Cell Res. 2009 Sep 10;315(15):2529-38.
Genome-wide analysis of small RNA and novel MicroRNA discovery in human acute lymphoblastic leukemia based on extensive
sequencing approach.
Zhang H, Yang JH, Zheng YS, Zhang P, Chen X, Wu J, Xu L, Luo XQ, Ke ZY, Zhou H, Qu LH, Chen YQ.
PLoS One. 2009 Sep 2;4(9):e6849.
MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.
San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, Vilas-Zornoza A, Rodríguez-Otero P, Calasanz
MJ, Prósper F, Agirre X.
Mol Cancer. 2009 Sep 1;8:69.
MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.
Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, Burchard J, Dai X, Chang AN, Diaz RL, Marszalek JR, Bartz SR, Carleton M,
Cleary MA, Linsley PS, Grandori C.
Cell Cycle. 2009 Sep 1;8(17):2756-68.
Regulation of p27Kip1 by miRNA 221/222 in glioblastoma.
Lorimer IA.
Cell Cycle. 2009 Sep 1;8(17):2685.
Linking metastasis suppression with metastamiR regulation.
Edmonds MD, Hurst DR, Welch DR.
Cell Cycle. 2009 Sep 1;8(17):2673-5.
Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection.
Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT.
Clin Cancer Res. 2009 Sep 1;15(17):5473-7.
microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies.
Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, Cheuk AT, Smith MA, Houghton P, Morton C, Khan J.
Clin Cancer Res. 2009 Sep 1;15(17):5560-8.
MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas.
Navarro A, Beà S, Fernández V, Prieto M, Salaverria I, Jares P, Hartmann E, Mozos A, López-Guillermo A, Villamor N, Colomer D, Puig
X, Ott G, Solé F, Serrano S, Rosenwald A, Campo E, Hernández L.
Cancer Res. 2009 Sep 1;69(17):7071-8.
MicroRNAs: new players in acute myeloid leukaemia.
Havelange V, Garzon R, Croce CM.
Br J Cancer. 2009 Sep 1;101(5):743-8.
Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation.
Valeri N, Vannini I, Fanini F, Calore F, Adair B, Fabbri M.
Mamm Genome. 2009 Sep-Oct;20(9-10):573-80.
Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue.
Ahmed FE, Jeffries CD, Vos PW, Flake G, Nuovo GJ, Sinar DR, Naziri W, Marcuard SP.
Cancer Genomics Proteomics. 2009 Sep-Oct;6(5):281-95.
Towards targeted epigenetic therapy of cancer.
Magic Z, Supic G, Brankovic-Magic M.
J BUON. 2009 Sep;14 Suppl 1:S79-88.
New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma.
Ji J, Wang XW.
Cancer Biol Ther. 2009 Sep;8(18):1686-93.
Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.
Salerno E, Scaglione BJ, Coffman FD, Brown BD, Baccarini A, Fernandes H, Marti G, Raveche ES.
Mol Cancer Ther. 2009 Sep;8(9):2684-92.
Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway
analysis.
Tömböl Z, Szabó PM, Molnár V, Wiener Z, Tölgyesi G, Horányi J, Riesz P, Reismann P, Patócs A, Likó I, Gaillard RC, Falus A, Rácz K,
Igaz P.
Endocr Relat Cancer. 2009 Sep;16(3):895-906.
MicroRNAs in clinical oncology: at the crossroads between promises and problems.
Metias SM, Lianidou E, Yousef GM.
J Clin Pathol. 2009 Sep;62(9):771-6.
miRNAs modulate the drug response of tumor cells.
Wu X, Xiao H.
Sci China C Life Sci. 2009 Sep;52(9):797-801.
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H.
Breast Cancer Res Treat. 2009 Sep;117(1):131-40.
Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
van der Kwast TH, Bapat B.
Curr Opin Urol. 2009 Sep;19(5):516-21.
Towards the definition of prostate cancer-related microRNAs: where are we now?
Gandellini P, Folini M, Zaffaroni N.
Trends Mol Med. 2009 Sep;15(9):381-90.
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease.
Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S.
Cancer Prev Res (Phila Pa). 2009 Sep;2(9):807-13.
Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light.
Izzotti A, Calin GA, Steele VE, Croce CM, De Flora S.
FASEB J. 2009 Sep;23(9):3243-50.
[Upper G.I. cancer: the esophagus and stomach. II. The current status of comprehensive gene analysis of esophageal cancer]
Shuto A, Tanaka F, Mimori K, Fujita H, Shirouzu K, Mori M.
Gan To Kagaku Ryoho. 2009 Sep;36(9):1435-41.
Tumour suppression by p53: the importance of apoptosis and cellular senescence.
Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y.
J Pathol. 2009 Sep;219(1):3-15.
c-Rel is a transcriptional repressor of EPHB2 in colorectal cancer.
Fu T, Li P, Wang H, He Y, Luo D, Zhang A, Tong W, Zhang L, Liu B, Hu C.
J Pathol. 2009 Sep;219(1):103-13.
Minireview: epigenetic changes in ovarian cancer.
Balch C, Fang F, Matei DE, Huang TH, Nephew KP.
Endocrinology. 2009 Sep;150(9):4003-11.
Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression.
Sun Q, Cong R, Yan H, Gu H, Zeng Y, Liu N, Chen J, Wang B.
Oncol Rep. 2009 Sep;22(3):563-7.
Is microRNA-143 really a turncoat of tumor suppressor microRNA in hepatitis B virus-related hepatocellular carcinoma?
Zhang R, Wang L, Yang AG.
Hepatology. 2009 Sep;50(3):987
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence.
Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR, Ji H, Vojtesek B,
Bourdon JC, Lane DP, Harris CC.
Nat Cell Biol. 2009 Sep;11(9):1135-42.
Helicobacter pylori and gastric cancer: possible role of microRNAs in this intimate relationship.
Belair C, Darfeuille F, Staedel C.
Clin Microbiol Infect. 2009 Sep;15(9):806-12.
Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation.
Kaddar T, Rouault JP, Chien WW, Chebel A, Gadoux M, Salles G, Ffrench M, Magaud JP.
Biol Cell. 2009 Sep;101(9):511-24.
miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1.
Li KK, Pang JC, Ching AK, Wong CK, Kong X, Wang Y, Zhou L, Chen Z, Ng HK.
Hum Pathol. 2009 Sep;40(9):1234-43.
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X.
Gynecol Oncol. 2009 Sep;114(3):457-64.
Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte
proliferation.
Kaddar T, Chien WW, Bertrand Y, Pages MP, Rouault JP, Salles G, Ffrench M, Magaud JP.
Leuk Res. 2009 Sep;33(9):1217-23.
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells.
Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, Desano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS, Xu L.
PLoS One. 2009 Aug 28;4(8):e6816.
Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells.
Guttilla IK, White BA.
J Biol Chem. 2009 Aug 28;284(35):23204-16.
MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme.
Li Y, Li W, Yang Y, Lu Y, He C, Hu G, Liu H, Chen J, He J, Yu H.
Brain Res. 2009 Aug 25;1286:13-8.
ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of
miR-27b regulation.
Wang Y, Rathinam R, Walch A, Alahari SK.
J Biol Chem. 2009 Aug 21;284(34):23094-106.
Lung cancer xenografting alters microRNA profile but not immunophenotype.
Bogner PN, Patnaik SK, Pitoniak R, Kannisto E, Repasky E, Hylander B, Yendamuri S, Ramnath N.
Biochem Biophys Res Commun. 2009 Aug 21;386(2):305-10.
MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines.
Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J.
PLoS One. 2009 Aug 18;4(8):e6677.
MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer.
Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li JJ, Röcken C, Ebert MP, Kwok TT, Sung JJ.
Br J Cancer. 2009 Aug 18;101(4):699-706.
Role of miRNAs in the progression of malignant melanoma.
Mueller DW, Bosserhoff AK.
Br J Cancer. 2009 Aug 18;101(4):551-6.
MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression.
Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, Mongera S, Postma C, Meijerink WJ, Carvalho B, Meijer GA.
Br J Cancer. 2009 Aug 18;101(4):707-14.
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth
factor receptor therapy.
Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C.
Clin Cancer Res. 2009 Aug 15;15(16):5060-72.
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.
Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M.
Clin Cancer Res. 2009 Aug 15;15(16):5073-81.
MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY, Rennie PS, Jia WW.
Clin Cancer Res. 2009 Aug 15;15(16):5126-35.
IRS-1 and microRNAs: partners in growth regulation.
Shaw LM.
Cell Cycle. 2009 Aug 15;8(16):2485-6.
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells.
Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH.
Cancer Res. 2009 Aug 15;69(16):6704-12.
MicroRNA involvement in glioblastoma pathogenesis.
Novakova J, Slaby O, Vyzula R, Michalek J.
Biochem Biophys Res Commun. 2009 Aug 14;386(1):1-5.
Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells
of Emicro-MiR-155 transgenic mice.
Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR, Shidham A, Croce CM.
Blood. 2009 Aug 13;114(7):1374-82.
Preliminary validation of ERBB2 expression regulated by miR-548d-3p and miR-559.
Chen H, Sun JG, Cao XW, Ma XG, Xu JP, Luo FK, Chen ZT.
Biochem Biophys Res Commun. 2009 Aug 7;385(4):596-600.
Nicotine, atrial fibrosis, and atrial fibrillation: do microRNAs help to clear the smoke?
Goette A.
Cardiovasc Res. 2009 Aug 1;83(3):421-2.
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human
solid tumors.
Xu H, Cheung IY, Guo HF, Cheung NK.
Cancer Res. 2009 Aug 1;69(15):6275-81.
HuR recruits let-7/RISC to repress c-Myc expression.
Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, Gorospe M.
Genes Dev. 2009 Aug 1;23(15):1743-8.
Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas.
Pedersen IM, Otero D, Kao E, Miletic AV, Hother C, Ralfkiaer E, Rickert RC, Gronbaek K, David M.
EMBO Mol Med. 2009 Aug;1(5):288-95.
The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal
phenotype in MCF-7 breast cancer cells.
Adams BD, Cowee DM, White BA.
Mol Endocrinol. 2009 Aug;23(8):1215-30.
Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells.
Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X, Liu CG, Yang JM.
Autophagy. 2009 Aug;5(6):816-23.
miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.
Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, Sarkar FH.
Stem Cells. 2009 Aug;27(8):1712-21.
miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1.
Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, Wistuba II, Ji L, Roth JA, Minna JD, Pertsemlidis A.
Mol Cancer Res. 2009 Aug;7(8):1234-43.
Cancer epigenetics and biology symposium: Barcelona, May 28-29, 2009.
Rattner BP.
Epigenetics. 2009 Aug;4(6):421-4.
MicroRNA expression profile in non-cancerous colonic tissue associated with lymph node metastasis of colon cancer.
Huang ZM, Yang J, Shen XY, Zhang XY, Meng FS, Xu JT, Zhang BF, Gao HJ.
J Dig Dis. 2009 Aug;10(3):188-94.
[MicroRNA in uro-oncology : New hope for the diagnosis and treatment of tumors?]
Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, Erbersdobler A, Stephan C, Jung K.
Urologe A. 2009 Aug;48(8):877-85.
Role of microRNA-221/-222 in cancer development and progression.
Sun T, Yang M, Kantoff P, Lee GS.
Cell Cycle. 2009 Aug;8(15):2315-6.
The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer.
Friedman JM, Jones PA, Liang G.
Cell Cycle. 2009 Aug;8(15):2313-4.
MicroRNAs in the pathogenesis of Lung Cancer.
Wu X, Piper-Hunter MG, Crawford M, Nuovo GJ, Marsh CB, Otterson GA, Nana-Sinkam SP.
J Thorac Oncol. 2009 Aug;4(8):1028-34.
Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J.
Ann Surg Oncol. 2009 Aug;16(8):2339-50.
Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer.
McCafferty MP, McNeill RE, Miller N, Kerin MJ.
Breast Cancer Res Treat. 2009 Aug;116(3):425-32.
Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and
expression of let-7a and IGF-II.
Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, de la Longrais IA, Preti M, Menato G, Yu H.
Eur J Cancer. 2009 Aug;45(12):2212-8.
Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor
receptor mutation.
Cho WC, Chow AS, Au JS.
Eur J Cancer. 2009 Aug;45(12):2197-206.
miR-21 as a key regulator of oncogenic processes.
Selcuklu SD, Donoghue MT, Spillane C.
Biochem Soc Trans. 2009 Aug;37(Pt 4):918-25.
MicroRNA MiR-17 retards tissue growth and represses fibronectin expression.
Shan SW, Lee DY, Deng Z, Shatseva T, Jeyapalan Z, Du WW, Zhang Y, Xuan JW, Yee SP, Siragam V, Yang BB.
Nat Cell Biol. 2009 Aug;11(8):1031-8.
Identification of novel HMGA2 fusion sequences in lipoma: evidence that deletion of let-7 miRNA consensus binding site 1 in the HMGA2 3'
UTR is not critical for HMGA2 transcriptional upregulation.
Wang X, Hulshizer RL, Erickson-Johnson MR, Flynn HC, Jenkins RB, Lloyd RV, Oliveira AM.
Genes Chromosomes Cancer. 2009 Aug;48(8):673-8.
Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155.
Levati L, Alvino E, Pagani E, Arcelli D, Caporaso P, Bondanza S, Di Leva G, Ferracin M, Volinia S, Bonmassar E, Croce CM, D'Atri S.
Int J Oncol. 2009 Aug;35(2):393-400.
Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism.
Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G, Anant S, Houchen CW.
Gastroenterology. 2009 Aug;137(2):649-59
Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin
expression.
Zhang X, Liu S, Hu T, Liu S, He Y, Sun S.
Hepatology. 2009 Aug;50(2):490-9.
Estradiol-regulated microRNAs control estradiol response in breast cancer cells.
Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, Brown M, Hammond S, Srour EF, Liu Y, Nakshatri H.
Nucleic Acids Res. 2009 Aug;37(14):4850-61.
MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia.
Mott JL.
Hepatology. 2009 Aug;50(2):630-7.
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells.
Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, Qin LX, Yang W, Wang HY, Tang ZY, Croce
CM, Wang XW.
Hepatology. 2009 Aug;50(2):472-80.
The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic
differentiation.
Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, Tuschl T, Ponzetto C.
J Clin Invest. 2009 Aug;119(8):2366-78.
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell.
Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z.
RNA. 2009 Aug;15(8):1443-61.
Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway.
La Rocca G, Badin M, Shi B, Xu SQ, Deangelis T, Sepp-Lorenzinoi L, Baserga R.
J Cell Physiol. 2009 Aug;220(2):485-91.
Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H.
Gynecol Oncol. 2009 Aug;114(2):253-9.
Dicer and outcomes in patients with acute myeloid leukemia (AML).
Martin MG, Payton JE, Link DC.
Leuk Res. 2009 Aug;33(8):e127.
Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human
gastric cancer cells.
Saito Y, Suzuki H, Tsugawa H, Nakagawa I, Matsuzaki J, Kanai Y, Hibi T.
Oncogene. 2009 Jul 30;28(30):2738-44.
Ionizing radiation-induced oxidative stress alters miRNA expression.
Simone NL, Soule BP, Ly D, Saleh AD, Savage JE, Degraff W, Cook J, Harris CC, Gius D, Mitchell JB.
PLoS One. 2009 Jul 27;4(7):e6377.
Cancer: Three birds with one stone.
Toledo F, Bardot B.
Nature. 2009 Jul 23;460(7254):466-7.
Modulation of microRNA processing by p53.
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K.
Nature. 2009 Jul 23;460(7254):529-33.
MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response.
Pothof J, Verkaik NS, van IJcken W, Wiemer EA, Ta VT, van der Horst GT, Jaspers NG, van Gent DC, Hoeijmakers JH, Persengiev SP.
EMBO J. 2009 Jul 22;28(14):2090-9.
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.
Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, Gemma A, Kudoh S, Croce CM,
Harris CC.
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12085-90.
Growth inhibition by microRNAs that target the insulin receptor substrate-1.
La Rocca G, Shi B, Badin M, De Angelis T, Sepp-Lorenzino L, Baserga R.
Cell Cycle. 2009 Jul 15;8(14):2255-9.
Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells.
Hsu PY, Deatherage DE, Rodriguez BA, Liyanarachchi S, Weng YI, Zuo T, Liu J, Cheng AS, Huang TH.
Cancer Res. 2009 Jul 15;69(14):5936-45.
microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis.
Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y.
Cancer Res. 2009 Jul 15;69(14):5970-7.
MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions.
Reddy SD, Pakala SB, Ohshiro K, Rayala SK, Kumar R.
Cancer Res. 2009 Jul 15;69(14):5639-42.
MicroRNA classifiers for predicting prognosis of squamous cell lung cancer.
Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG.
Cancer Res. 2009 Jul 15;69(14):5776-83.
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P,
Negrini M, Bolondi L.
Cancer Res. 2009 Jul 15;69(14):5761-7.
Identification of novel microRNA targets based on microRNA signatures in bladder cancer.
Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G,
Nakagawa M, Seki N.
Int J Cancer. 2009 Jul 15;125(2):345-52.
Detection of cancer with serum miRNAs on an oligonucleotide microarray.
Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B.
PLoS One. 2009 Jul 14;4(7):e6229.
Tumor-suppressive microRNAs in Lung cancer: diagnostic and therapeutic opportunities.
Sempere LF, Liu X, Dmitrovsky E.
ScientificWorldJournal. 2009 Jul 13;9:626-8.
Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma.
Lu Y, Ryan SL, Elliott DJ, Bignell GR, Futreal PA, Ellison DW, Bailey S, Clifford SC.
PLoS One. 2009 Jul 7;4(7):e6159.
Reflections on miR-ing effects in metastasis.
Dumont N, Tlsty TD.
Cancer Cell. 2009 Jul 7;16(1):3-4.
Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion.
Huang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, Brincat A, Horiuchi D, Lebbink RJ, Mo YY, Goga A, McManus MT.
J Biol Chem. 2009 Jul 3;284(27):18515-24.
Evaluation of the 8q24 prostate cancer risk locus and MYC expression.
Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL,
Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG,
Srivastava S, Freedman ML.
Cancer Res. 2009 Jul 1;69(13):5568-74.
miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in
non-small cell lung cancer.
Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunner T, Vassella E.
Cancer Res. 2009 Jul 1;69(13):5553-9.
Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy.
Subramanian H, Roy HK, Pradhan P, Goldberg MJ, Muldoon J, Brand RE, Sturgis C, Hensing T, Ray D, Bogojevic A, Mohammed J,
Chang JS, Backman V.
Cancer Res. 2009 Jul 1;69(13):5357-63.
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in
cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll
AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD.
J Clin Oncol. 2009 Jul 1;27(19):3198-204.
Prognostic significance of HPV physical status and integration sites in cervical cancer.
Nambaru L, Meenakumari B, Swaminathan R, Rajkumar T.
Asian Pac J Cancer Prev. 2009 Jul-Sep;10(3):355-60.
Pathogenetic and clinical relevance of microRNAs in colorectal cancer.
Valeri N, Croce CM, Fabbri M.
Cancer Genomics Proteomics. 2009 Jul-Aug;6(4):195-204.
Translational regulation mechanisms of AP-1 proteins.
Vesely PW, Staber PB, Hoefler G, Kenner L.
Mutat Res. 2009 Jul-Aug;682(1):7-12.
MicroRNA expression profile based cancer classification using Default ARTMAP.
Xu R, Xu J, Wunsch DC 2nd.
Neural Netw. 2009 Jul-Aug;22(5-6):774-80.
Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation.
Bruchova H, Yoon D, Agarwal AM, Swierczek S, Prchal JT.
Blood Cells Mol Dis. 2009 Jul-Aug;43(1):81-7.
Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular
lymphoma.
Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S, Saunders NJ, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS.
J Cell Mol Med. 2009 Jul;13(7):1248-60.
CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis.
Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuutila S.
Genes Chromosomes Cancer. 2009 Jul;48(7):615-23.
Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy.
Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E, Gollin SM.
Genes Chromosomes Cancer. 2009 Jul;48(7):569-82.
Molecular markers in acute myeloid leukemia.
Marcucci G.
Clin Adv Hematol Oncol. 2009 Jul;7(7):448-51.
NCCN task force report: molecular markers in leukemias and lymphomas.
Radich JP, Zelenetz AD, Chan WC, Croce CM, Czuczman MS, Erba HP, Horning SJ, Houldsworth J, Smith BD, Snyder DS, Sundar HM,
Wetzler M, Winter JN.
J Natl Compr Canc Netw. 2009 Jul;7 Suppl 4:S1-34
MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain
tumors.
Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A, Kharenko O, Sitbon E,
Lithwick Yanai G, Elyakim E, Cholakh H, Gibori H, Spector Y, Bentwich Z, Barshack I, Rosenfeld N.
Brain Pathol. 2009 Jul;19(3):375-83.
Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma.
Liu M, Wu H, Liu T, Li Y, Wang F, Wan H, Li X, Tang H.
Cell Res. 2009 Jul;19(7):828-37.
BMPRII is a direct target of miR-21.
Qin W, Zhao B, Shi Y, Yao C, Jin L, Jin Y.
Acta Biochim Biophys Sin (Shanghai). 2009 Jul;41(7):618-23.
Updates in cancer research: insights from the AACR 100th Annual Meeting.
Cho WC.
Expert Rev Mol Diagn. 2009 Jul;9(5):411-6.
Current molecular diagnostics of breast cancer and the potential incorporation of microRNA.
Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK, Tangrea MA.
Expert Rev Mol Diagn. 2009 Jul;9(5):455-67.
MicroRNA regulatory network in human colorectal cancer.
Tang JT, Fang JY.
Mini Rev Med Chem. 2009 Jul;9(8):921-6.
Multi-class cancer classification through gene expression profiles: microRNA versus mRNA.
Peng S, Zeng X, Li X, Peng X, Chen L.
J Genet Genomics. 2009 Jul;36(7):409-16.
Small RNA: a large contributor to carcinogenesis?
Bhatti I, Lee A, Lund J, Larvin M.
J Gastrointest Surg. 2009 Jul;13(7):1379-88.
Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma.
Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, Tan TM.
Cancer Sci. 2009 Jul;100(7):1234-42.
Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells.
Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, Lee SM, Lee SJ, Park IC, Jin YW, An S.
Int J Mol Med. 2009 Jul;24(1):45-50.
Epigenetics in human melanoma.
Howell PM Jr, Liu S, Ren S, Behlen C, Fodstad O, Riker AI.
Cancer Control. 2009 Jul;16(3):200-18.
The role of microRNA in human leukemia: a review.
Yendamuri S, Calin GA.
Leukemia. 2009 Jul;23(7):1257-63.
miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors.
Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF, Maio F, Cama A, Germanò A, Vita G, Tomasello F.
J Neurooncol. 2009 Jul;93(3):325-32.
miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA.
Pandey DP, Picard D.
Mol Cell Biol. 2009 Jul;29(13):3783-90.
MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells.
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM.
Hepatology. 2009 Jul;50(1):113-21.
Alteration of miRNA profiles by ionizing radiation in A549 human non-small cell lung cancer cells.
Shin S, Cha HJ, Lee EM, Lee SJ, Seo SK, Jin HO, Park IC, Jin YW, An S.
Int J Oncol. 2009 Jul;35(1):81-6.
MicroRNA profiling of human kidney cancer subtypes.
Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT.
Int J Oncol. 2009 Jul;35(1):109-14.
Differential expression of microRNA 181b and microRNA 21 in hyperplastic polyps and sessile serrated adenomas of the colon.
Schmitz KJ, Hey S, Schinwald A, Wohlschlaeger J, Baba HA, Worm K, Schmid KW.
Virchows Arch. 2009 Jul;455(1):49-54.
miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of
malignant melanoma.
Mueller DW, Rehli M, Bosserhoff AK.
J Invest Dermatol. 2009 Jul;129(7):1740-51.
Lin28 promotes transformation and is associated with advanced human malignancies.
Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS,
Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH,
Daley GQ.
Nat Genet. 2009 Jul;41(7):843-8.
MicroRNAs are novel biomarkers of colorectal cancer.
Aslam MI, Taylor K, Pringle JH, Jameson JS.
Br J Surg. 2009 Jul;96(7):702-10.
Tumors line up for a letdown.
Mendell JT.
Nat Genet. 2009 Jul;41(7):768-9.